cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13130/rd_unimi/xu1sm0/i5lhzw
title: Giugno_1893_Pagina_015.jpg

description: Bulletin of 1893/06/04
DOI: 10.25934/pr00012208
title: A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

description: The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active PsA despite current or previous NSAID or DMARD therapy
DOI: 10.13130/rd_unimi/awv4gb/a9l8ue
title: Gennaio_1896_Pagina_118.jpg

description: Bulletin of 1896/01/30
DOI: 10.13130/rd_unimi/cbrkhv/m7myj2
title: Gennaio_1927_Pagina_030.jpg

description: Bulletin of 1927/01/08
DOI: 10.13130/rd_unimi/v8alup/i1w7p4
title: Giugno_1891_Pagina_037.jpg

description: Bulletin of 1891/06/10
DOI: 10.25934/pr00012209
title: A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

description: A single-arm, open-label, two-stage multicenter, phase II study. Patients were pre-screened for ALK positive status. Treatment with LDK378 at 750 mg qd was continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anticancer therapy and/or died. LDK378 was continued beyond RECIST defined progressive disease (PD) as assessed by the investigator, if in the judgment of the investigator, there was evidence of clinical benefit. Patients who discontinued the study medication in the absence of progression continued to be followed for tumor assessment until the time of PD as assessed by the investigator. Male and female patients aged 18 or over with ALK-rearranged non-small cell cancer (NSCLC) were screened for eligibility. Patients had to have received no prior crizotinib, and had to be chemotherapy-naïve or been pretreated with cytotoxic chemotherapy (up to three prior lines).
DOI: 10.13130/rd_unimi/gsbgp1/2lnkv0
title: Giugno_1889_Pagina_057.jpg

description: Bulletin of 1889/06/15
DOI: 10.13130/rd_unimi/rjrjox/alt1il
title: Luglio_1895_Pagina_065.jpg

description: Bulletin of 1895/07/17
DOI: 10.25574/03140
title: Chandra X-ray Observatory ObsId 03140

description: PROBING THE X-RAY EMISSION OF HIGH LUMINOSITY EMISSION LINE GALAXIES: QUASAR-2s AND THE STARBURST-AGN CONNECTION
DOI: 10.25934/pr00012210
title: An Open-label Phase II (Proof of Concept (POC)) Trial of PKC412 Monotherapy in Participants With Acute Myeloid Leukemia (AML) and Participants With High Risk Myelodysplastic Syndrome (MDS) (CPKC412A2104 Core); An Open-label, Randomized Phase II POC Trial in PKC412 in Participants With AML and Participants With High Risk MDS With Either Wild Type or Mutated FLT3 (CPKC412A2104E1); and An Open-label, Randomized Phase 1/II POC Trial in PKC412 in Participants With AML and Participants With High Risk MDS With Either Wild Type or Mutated FLT3 (CPKC412A2104E2)

description: CPKC412A2104 core had a 2 stage design. In stage 1, eight participants were treated. If at least one participant showed a clinical response, four more participants were recruited to stage 2. The trial was to be stopped if no participants showed a response in stage 1. POC was achieved if at least 2 participants out of 12 responded. In PKC412A2104E1, participants with AML or high risk MDS with wild-type or mutant FTL3 who had not previously received a FLT3 inhibitor were randomized to receive continuous twice daily oral doses of either 50 or 100 mg midostaurin in 1 28-day cycle regimen. Participants were to be treated until disease progression or the occurrence of unacceptable treatment-related toxicity. PKC412A2104 E2 contained 2 dosing regimens: 1) intra-participant midostaurin dose escalation and 2) midostaurin with itraconazole in participants with AML and high risk MDS irrespective of FLT3 status. Eligible participants were alternately assigned to the regimens. At the Investigator's discretion, intra-participant dose escalation was allowed for any previously enrolled CPKC412A2104E1 participant receiving midostaurin at the time of the approval of amendment 4. Participants were treated until the time of disease progression.
DOI: 10.5281/zenodo.17953432
title: X-ray Diffraction Data for 3C-SiC/Si Heterostructures with and without Porous Silicon Buffer Layer

description: This dataset contains X-ray diffraction (XRD) data acquired for cubic silicon carbide (3C-SiC) thin films heteroepitaxially grown on silicon substrates, with and without an intermediate porous silicon (por-Si) buffer layer.

The data were collected to characterize the crystal structure, peak broadening, and residual lattice strain in 3C-SiC/Si heterostructures and to enable a comparative assessment of stress relaxation induced by a compliant porous silicon interlayer.

Two sample series are included:



S-ref — 3C-SiC films grown directly on monocrystalline silicon substrates without a buffer layer;

S-buf — 3C-SiC films grown on silicon substrates incorporating a porous silicon buffer layer.


The dataset includes raw diffraction patterns, processed peak data, and tabulated peak parameters used for quantitative structural analysis. Particular attention is given to the (111) and (220) reflections of 3C-SiC, which are sensitive to residual biaxial stress and crystalline quality.

The data support reproducibility of XRD-based structural analysis and may be reused for comparative studies of stress mitigation strategies in semiconductor heterostructures.

Methods

X-ray diffraction measurements were performed at room temperature using a laboratory powder diffractometer operated in θ–2θ geometry. All samples were measured under identical instrumental conditions to ensure direct comparability between buffered and buffer-free heterostructures.

Diffraction patterns were collected over an angular range sufficient to resolve the characteristic reflections of cubic silicon carbide and the silicon substrate. Instrumental broadening was evaluated using a crystalline standard and taken into account during peak analysis.

Data processing included background subtraction, peak fitting, and determination of peak positions and full widths at half maximum (FWHM). The extracted parameters were used to assess relative changes in lattice spacing, peak broadening, and microstructural quality between the two sample series. Where applicable, the data were further employed for size–strain analysis using established line-broadening approaches.

Detailed growth conditions, full instrumental settings, and extended modeling procedures are intentionally not disclosed at this stage and may be provided in future versions of the dataset upon completion of the associated research project.

 

Content of the dataset

The dataset includes:



Raw XRD diffraction patterns as acquired from the diffractometer;

Processed diffraction data after background correction and peak fitting;

Tabulated peak parameters (2θ position, FWHM, interplanar spacing) in open formats;

Sample identification table linking diffraction data to sample series (S-ref, S-buf);

Derived structural parameters used for comparative analysis of buffered and unbuffered heterostructures.
DOI: 10.13130/rd_unimi/6np0bt/u9qtts
title: Gennaio_1894_Pagina_123.jpg

description: Bulletin of 1894/01/31
DOI: 10.13130/rd_unimi/cbrkhv/n0k2tu
title: Gennaio_1927_Pagina_031.jpg

description: Bulletin of 1927/01/08
DOI: 10.25934/pr00012211
title: A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension

description: A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
DOI: 10.5281/zenodo.17953431
title: X-ray Diffraction Data for 3C-SiC/Si Heterostructures with and without Porous Silicon Buffer Layer

description: This dataset contains X-ray diffraction (XRD) data acquired for cubic silicon carbide (3C-SiC) thin films heteroepitaxially grown on silicon substrates, with and without an intermediate porous silicon (por-Si) buffer layer.

The data were collected to characterize the crystal structure, peak broadening, and residual lattice strain in 3C-SiC/Si heterostructures and to enable a comparative assessment of stress relaxation induced by a compliant porous silicon interlayer.

Two sample series are included:



S-ref — 3C-SiC films grown directly on monocrystalline silicon substrates without a buffer layer;

S-buf — 3C-SiC films grown on silicon substrates incorporating a porous silicon buffer layer.


The dataset includes raw diffraction patterns, processed peak data, and tabulated peak parameters used for quantitative structural analysis. Particular attention is given to the (111) and (220) reflections of 3C-SiC, which are sensitive to residual biaxial stress and crystalline quality.

The data support reproducibility of XRD-based structural analysis and may be reused for comparative studies of stress mitigation strategies in semiconductor heterostructures.

Methods

X-ray diffraction measurements were performed at room temperature using a laboratory powder diffractometer operated in θ–2θ geometry. All samples were measured under identical instrumental conditions to ensure direct comparability between buffered and buffer-free heterostructures.

Diffraction patterns were collected over an angular range sufficient to resolve the characteristic reflections of cubic silicon carbide and the silicon substrate. Instrumental broadening was evaluated using a crystalline standard and taken into account during peak analysis.

Data processing included background subtraction, peak fitting, and determination of peak positions and full widths at half maximum (FWHM). The extracted parameters were used to assess relative changes in lattice spacing, peak broadening, and microstructural quality between the two sample series. Where applicable, the data were further employed for size–strain analysis using established line-broadening approaches.

Detailed growth conditions, full instrumental settings, and extended modeling procedures are intentionally not disclosed at this stage and may be provided in future versions of the dataset upon completion of the associated research project.

 

Content of the dataset

The dataset includes:



Raw XRD diffraction patterns as acquired from the diffractometer;

Processed diffraction data after background correction and peak fitting;

Tabulated peak parameters (2θ position, FWHM, interplanar spacing) in open formats;

Sample identification table linking diffraction data to sample series (S-ref, S-buf);

Derived structural parameters used for comparative analysis of buffered and unbuffered heterostructures.
DOI: 10.13130/rd_unimi/awv4gb/elnziu
title: Gennaio_1896_Pagina_119.jpg

description: Bulletin of 1896/01/30
DOI: 10.13130/rd_unimi/nsvbhr/ifyk4q
title: Giugno_1890_Pagina_041.jpg

description: Bulletin of 1890/06/11
DOI: 10.13130/rd_unimi/v8alup/imvztn
title: Giugno_1891_Pagina_038.jpg

description: Bulletin of 1891/06/10
DOI: 10.13130/rd_unimi/xu1sm0/vil1u4
title: Giugno_1893_Pagina_016.jpg

description: Bulletin of 1893/06/04
DOI: 10.25934/pr00012212
title: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

description: The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population
DOI: 10.25934/pr00012213
title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

description: This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with head and neck cancer following surgery. Lapatinib or placebo will be administered post-operatively in combination with chemoradiotherapy followed by maintenance with lapatinib or placebo for 1 year. The primary goal is to determine if lapatinib is effective at reducing the recurrence of the disease in these high-risk patients.
DOI: 10.13130/rd_unimi/gsbgp1/xdbwum
title: Giugno_1889_Pagina_058.jpg

description: Bulletin of 1889/06/15
DOI: 10.13130/rd_unimi/jvs9pt/gbjaqj
title: Giugno_1892_Pagina_016.jpg

description: Bulletin of 1892/06/04
DOI: 10.13130/rd_unimi/rjrjox/ajtzcs
title: Luglio_1895_Pagina_066.jpg

description: Bulletin of 1895/07/17
DOI: 10.25574/03141
title: Chandra X-ray Observatory ObsId 03141

description: PROBING THE X-RAY EMISSION OF HIGH LUMINOSITY EMISSION LINE GALAXIES: QUASAR-2s AND THE STARBURST-AGN CONNECTION
DOI: 10.25934/pr00012214
title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer

description: This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.
DOI: 10.13130/rd_unimi/6np0bt/tfr3is
title: Gennaio_1894_Pagina_124.jpg

description: Bulletin of 1894/01/31
DOI: 10.13130/rd_unimi/cbrkhv/jyei5w
title: Gennaio_1927_Pagina_032.jpg

description: Bulletin of 1927/01/08
DOI: 10.25934/pr00012215
title: β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

description: The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
DOI: 10.13130/rd_unimi/nsvbhr/qvnhrl
title: Giugno_1890_Pagina_042.jpg

description: Bulletin of 1890/06/11
DOI: 10.13130/rd_unimi/v8alup/bvjp0j
title: Giugno_1891_Pagina_039.jpg

description: Bulletin of 1891/06/10
DOI: 10.13130/rd_unimi/xu1sm0/8bbma1
title: Giugno_1893_Pagina_017.jpg

description: Bulletin of 1893/06/05
DOI: 10.25934/pr00012216
title: A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.

description: The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and tolerability for the selection of an optimal dose in a later phase III study.Study Design Rationale An adaptive design was chosen to characterize the dose response curve of BAF312. In a first period of study ("Period 1"), three doses of BAF312 and placebo were tested for MRI efficacy. Based on an interim analysis (IA) after 3 months of treatment, two additional active doses for period 2 wereselected , thus allowing to optimize the overall determination of the dose response curve with 5 data points of active treatment, and placebo. The doses were kept blinded. The use of Modeling and Simulation allowed to establish the full range and dynamics of the dose-response curve in silico, and hence the definition of the optimal dose for later phase III studies.The choice of placebo as treatment control was essential to obtain information on the specific compared to non-specific effects of active treatment and provides the best way of evaluating the efficacy and of assessing the true safety and tolerability profile of BAF312. Short-term placebo exposure (6 (Period 1) or 3 (Period 2) months, respectively) was unlikely to lead to longer term differences in outcomes \[Polman, 2008\]. The use of an adaptive design strategy contributed to a significant reduction of placebo exposure, both in terms of the number of patients and duration, as compared to conventional trial models.Patients having completed the study within the protocol might be eligible for the Extension Phase study where they receive long-term BAF312 treatment (a separate protocol).
DOI: 10.13130/rd_unimi/awv4gb/9eypib
title: Gennaio_1896_Pagina_120.jpg

description: Bulletin of 1896/01/30
DOI: 10.13130/rd_unimi/jvs9pt/kehwme
title: Giugno_1892_Pagina_017.jpg

description: Bulletin of 1892/06/05
DOI: 10.13130/rd_unimi/rjrjox/qgdjvs
title: Luglio_1895_Pagina_055.jpg

description: Bulletin of 1895/07/14
DOI: 10.25574/03142
title: Chandra X-ray Observatory ObsId 03142

description: PROBING THE X-RAY EMISSION OF HIGH LUMINOSITY EMISSION LINE GALAXIES: QUASAR-2s AND THE STARBURST-AGN CONNECTION
DOI: 10.25934/pr00012217
title: A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

description: The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD.
DOI: 10.13130/rd_unimi/6np0bt/8kwsws
title: Giugno_1894_Pagina_001.jpg

description: Bulletin of 1894/06/01
DOI: 10.13130/rd_unimi/cbrkhv/noymph
title: Gennaio_1927_Pagina_033.jpg

description: Bulletin of 1927/01/09
DOI: 10.25934/pr00012218
title: A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

description: This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
DOI: 10.25934/pr00012219
title: A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen

description: This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
DOI: 10.13130/rd_unimi/gsbgp1/jguina
title: Giugno_1889_Pagina_059.jpg

description: Bulletin of 1889/06/15
DOI: 10.13130/rd_unimi/nsvbhr/ji6tjy
title: Giugno_1890_Pagina_043.jpg

description: Bulletin of 1890/06/11
DOI: 10.13130/rd_unimi/v8alup/pt3obg
title: Giugno_1891_Pagina_040.jpg

description: Bulletin of 1891/06/10
DOI: 10.25934/pr00012220
title: A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab

description: The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
DOI: 10.13130/rd_unimi/jvs9pt/o7uo1g
title: Giugno_1892_Pagina_018.jpg

description: Bulletin of 1892/06/05
DOI: 10.13130/rd_unimi/rjrjox/ikf7zc
title: Luglio_1895_Pagina_068.jpg

description: Bulletin of 1895/07/17
DOI: 10.13130/rd_unimi/xu1sm0/jynyp6
title: Giugno_1893_Pagina_018.jpg

description: Bulletin of 1893/06/05
DOI: 10.25574/03146
title: Chandra X-ray Observatory ObsId 03146

description: MAPPING THE REFLECTING REGIONS IN THE SEYFERT 2 GALAXY TOLOLO 0109-383
DOI: 10.25934/pr00012221
title: A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis

description: Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
DOI: 10.13130/rd_unimi/6np0bt/fpme9t
title: Giugno_1894_Pagina_002.jpg

description: Bulletin of 1894/06/01
DOI: 10.13130/rd_unimi/awv4gb/traogn
title: Gennaio_1896_Pagina_121.jpg

description: Bulletin of 1896/01/31
DOI: 10.13130/rd_unimi/cbrkhv/ivu7te
title: Gennaio_1927_Pagina_034.jpg

description: Bulletin of 1927/01/09
DOI: 10.25934/pr00012222
title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

description: The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
DOI: 10.13130/rd_unimi/gsbgp1/zofclc
title: Giugno_1889_Pagina_060.jpg

description: Bulletin of 1889/06/15
DOI: 10.13130/rd_unimi/nsvbhr/ietm1u
title: Giugno_1890_Pagina_044.jpg

description: Bulletin of 1890/06/11
DOI: 10.13130/rd_unimi/v8alup/qs8cca
title: Giugno_1891_Pagina_041.jpg

description: Bulletin of 1891/06/11
DOI: 10.25574/03149
title: Chandra X-ray Observatory ObsId 03149

description: CHANDRA OBSERVATIONS OF TYPE-2 LINERS: STARBURSTS OR AGNS ?
DOI: 10.25934/pr00012223
title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis

description: Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
DOI: 10.13130/rd_unimi/jvs9pt/lakn31
title: Giugno_1892_Pagina_019.jpg

description: Bulletin of 1892/06/05
DOI: 10.13130/rd_unimi/rjrjox/ddlg91
title: Luglio_1895_Pagina_070.jpg

description: Bulletin of 1895/07/18
DOI: 10.13130/rd_unimi/xu1sm0/x9cs6u
title: Giugno_1893_Pagina_019.jpg

description: Bulletin of 1893/06/05